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Abstract 
Background. To study the hematological complications of patients with the Shwachman-Diamond 
syndrome and their risk factors. 
 
Design and Methods. 102 patients, with a median follow-up of 11.6 years, were studied. Major 
hematological complications were considered in the case of definitive severe cytopenia (i.e. anemia < 
7g/dL or thrombocytopenia < 20 G/L), classified as malignant (myelodysplasia/leukemia) according to the 
2008 World Health Organization classification or as non-malignant.  
 
Results. Severe cytopenia were observed in 21 patients and classified as malignant severe cytopenia 
(n=9), non-malignant severe cytopenia (n=9) and in 3 cases malignant severe cytopenia was preceded by 
non-malignant severe cytopenia. 20-year cumulative risk of severe cytopenia was 24.3% (95% 
Confidence Interval 15.3%-38.5%). Young age at first symptoms (< 3 months) and low hematological 
parameters both at diagnosis of the disease and during the follow-up were associated with severe 
hematological complications (P<0.001). Fifteen novel SBDS mutations were identified. Genotype analysis 
showed no discernable prognostic value.  
 
Conclusions. Patients with Shwachman-Diamond syndrome with very early symptoms or cytopenia at 
diagnosis (even mild anemia or thrombocytopenia) should be considered at a high risk of severe 
hematological complications, malignant or non-malignant. Transient severe cytopenia or indolent 
cytogenetic clone had no deleterious value.  
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Introduction 
The Shwachman-Diamond syndrome (SDS) (OMIM 260400) is an autosomal recessive multisystem 
disorder characterized by exocrine pancreatic dysfunction, mild neutropenia and may be associated with 
metaphyseal dysostosis, mild intellectual retardation, or various other organ dysfunctions.1 
The SBDS gene, located on chromosome 7q11, is associated with the disease.2 SBDS protein is an 
essential cofactor for elongation factor 1 (EFL1), and together they directly catalyze eIF6 release from 
nascent 60S subunits of the ribosome by a mechanism requiring both GTP binding and hydrolysis.3 SBDS 
mutations arising from gene conversion are present in almost all patients, the compound heterozygous 
genotype p.[Lys62X]+[Cys84fs] being present in about 60% of patients.2 SDS is characterized by variable 
clinical phenotypes between and within families. Patients with SBDS mutations may have normal blood 
cell counts, even though their siblings are severely neutropenic at a comparable age. Some patients have 
severe exocrine pancreatic deficiency, while in other cases this disorder is only diagnosed by routine 
screening. The severity and course of the disease also vary, one third of patients developing major 
hematological complications.4 The latter are the main causes of early death and warrant a hematopoietic 
stem cell transplantation.5 No risk factors for these complications have been identified so far, although 
leukemia appears in the literature to be more frequent in males.1;6;7 This prompted us to analyze a cohort 
of 102 genotyped patients with SDS belonging to 93 families, for which exhaustive clinical features, 
hematological and biological parameters have been collected over a median follow-up of 11.6 years. 
 
Design and Methods 
Patients 
Patients included in this study were all registered in the French severe chronic neutropenia registry. The 
registry was initially created in 1993; since then, enrollment has been prospective. All types of congenital 
neutropenia were included8. Since 2008, the register was certified as a national registry by the health 
authorities, and completeness of cases was ascertained by controlling multiple sources. Thirty-five French 
pediatric hematology-oncology and gastro enterology units participated to this register. Data monitoring, 
based on medical charts, was done by a clinical research associate who visited each centre yearly. The 
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patient must provide written informed consent to be included in the registry. Several reports of the register 
are available elsewhere4;5;9-11  
The common definition of SDS was used.1 Briefly, SDS was diagnosed in patients with both neutropenia 
(with at least one complete blood count showing an absolute neutrophil count below 1.5 G/L) and exocrine 
pancreatic deficiency. In addition to this phenotype, recessive mutations of the SBDS gene were 
considered as diagnostic criteria of SDS. Of the 111 patients included in the registry with SDS diagnosis, 
105 patients were genotyped. No mutations were found in two patients and one patient was excluded 
because of lack of phenotypic information. Thus, this study involved 102 patients, all with proven SBDS 
mutations.  
 
Clinical investigation 
Demographic, auxologic, nutritional status, hematological parameters, liver tests, immunological tests and 
infectious status were recorded. Septicemia, cellulitis, bacterial or fungal pneumonia, osteitis, and liver 
abscess were considered as severe infections and were systemically recorded. Immunoglobulin levels 
were analyzed according to age.12  
Developmental retardation was considered as severe if the patient was unable to attend a normal school, 
even late, and thus required special schooling. Prematurity was defined by a gestational age below 37 
weeks, intrauterine growth retardation as a birth weight below 3 standard deviations (SD) for gestational 
age, and severe gastrointestinal complications as the need for nutritional support, either by enteral route 
with gastrostomy or by parenteral route. Orthopedic complications were considered to have occurred 
when orthopedic surgery (i.e. for hip dysplasia or scoliosis) was required. Age at diagnosis was defined by 
the age at the first pathological manifestation leading to the diagnosis of SDS.  
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Definition of hematological features and hematological complications 
Initial complete blood count (CBC) value was the median value of the three first CBC collected in the life 
of the patients. Baseline CBC were considered if they were collected during routine consultations, with the 
exception of periods with granulocyte colony-stimulating factor (G-CSF) therapy and any hematological 
complications defined below. Because neutropenia is part of the definition of the disease, hematological 
complications take into account a severe dysfunction in other hematopoietic lineages, i.e. anemia or 
thrombocytopenia. Severe cytopenia (SC) was considered in cases of profound anemia (hemoglobin [Hb] 
< 7g/dL) or profound thrombocytopenia (platelets < 20 G/L). The classification of SC was based on three 
criteria: bone marrow morphology and differential count, bone marrow cytogenetics and the duration of SC 
(less or more than 3 months). Bone marrow smears were centrally reviewed (OF) and classified according 
to the 2008 WHO classification, which is applicable to define acute leukemia and myelodysplastic 
syndrome (MDS).13-15 Indeed, the complications were categorized as follows: a) malignant definitive SC, 
i.e. myelodysplasia or acute leukemia according to the WHO 2008 classification; b) non-malignant 
definitive SC if the bone marrow smear did not show any malignant features according to the WHO 2008 
classification and if the bone marrow cytogenetic analyses were normal; c) transient SC if the latter lasted 
less than 3 months; d) clonal bone marrow cytogenetics, when a bone marrow cytogenetic clone was 
detected on routine bone marrow examination and in the absence of SC. Onset of non-malignant SC and 
malignant SC were considered as two distinct events in the same patient, if the two diagnoses were 
separated by at least three months. Myeloid blockage was defined according to previous study11.  
 
SBDS sequence analysis 
The patients or their parents gave their written informed consent for genetic testing. Genomic DNA was 
extracted from blood with standard procedures. The coding sequence and exon-intron boundaries of the 
SBDS gene were amplified by using the primers and polymerase chain reaction (PCR) conditions 
described by Boocock et al.2 PCR products were sequenced in both directions with the ABI PRISM Big 
Dye Terminator v1.1 Ready Reaction Cycle Sequencing kit (Applied Biosystems) on an ABI PRISM 3100 
Genetic Analyzer (Applied Biosystems). Sequences were analyzed with the Seqscape software v2.2 
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(Applied Biosystems). Mutations are numbered as recommended by the Human Genome Variation 
Society (http://www.hgvs.org/), using the reference sequence NM_016038.2. 
 
Statistical methods 
Stata® software version 10 was used for all statistical analyses. Lower and upper interquartile, and 
median values depict the distribution of quantitative variables. Differences between groups of patients 
were analyzed using Fisher’s exact test if the event was discrete and Wilcoxon’s test for quantitative 
variables. Survival was compared between groups of subjects using the log-rank test, and Cox model was 
used for multivariate analysis.16 As we performed repeated tests, P values <0.001 were considered to 
indicate statistical significance, unless otherwise stated. For survival analyses the endpoints were death, 
definitive SC (either malignant or non-malignant) and the period taken into account was the interval from 
birth to the event or to the last examination when no event occurred. The Kaplan-Meier method was used 
to estimate survival rates. The cut-off date was 30 September 2011. 
 
Results 
Demographic features and extra-hematopoietic characteristics  
One hundred and two patients were studied. There was a slight male predominance (58 males; 57%). The 
median follow-up was 11.6 years (p25: 6.2 years - p75: 20 years), corresponding to 1446 person-years. 
The 102 patients belonged to 93 distinct families. There were eight multiplex families, with two cases in 
seven families and three cases in one family. Median age at diagnosis was 0.55 years (p25: 0.18 years - 
p75: 1.8 years). The median gestational age was 40 weeks (p25: 38 weeks - p75: 41 weeks). There were 
only 11 premature births (13%) before 37 weeks of gestation. Median birth weight was 2840g (p25: 2440g 
- p75: 3190g) and 27 patients (26%) had intrauterine growth retardation ≥3 SD. Thirteen patients (16.7%) 
required nutrition assistance. Growth retardation (height ≥3 SD) was observed in 60 (61%). Severe bone 
complications leading to bone surgery were reported in only nine patients (9%). Severe mental retardation 
was present in 25 patients (34% of the 73 patients aged > 7 years). Heart abnormalities were observed in 
12 patients (12%) and consisted of heart malformations in six and cardiomyopathy in six. Labial cleft was 
observed in six patients. Finally, severe gastrointestinal symptoms requiring enteral or parenteral feeding 
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or gastrostomy was observed in 19 patients (19%), but were always transient, and observed in young age, 
at a median age of 0.6 years (p25: 0.2 years p75 0.9 years). 
 
Immuno-hematological features and infectious events 
At diagnosis of SDS, the initial absolute neutrophil count (ANC) was 0.82 G/L (p25: 0.5 - p75: 1.7 G/L). 
The median hemoglobin level was 11.4 g/dL (p25: 9.9 g/dL - p75 12.2 g/dL) and the median platelet count 
was 217 G/L (p25 142 - p75 319 G/L). At diagnosis, 38 patients had low blood cell count values with 23 
patients with ANC below 0.5 G/L, 11 with a platelet count below 100 G/L and 13 with hemoglobin below 9 
g/dL. 
During routine follow-up, a median of 17 baseline CBC values per patient were available (p25: 10 - p75: 
28). In all cases with serial CBC, hematological parameters fluctuated with time, without any detectable 
regular variation; online supplementary figure 1 shows the sequential variation of neutrophil count in two 
patients followed over a 35-year period. The median ANC was 0.75 G/L (p25: 0.56 G/L - p75: 1.32 G/L). 
The median hemoglobin level was 11.7 g/dL (p25: 11.1 g/dL - p75 12.4 g/dL) and the median platelet 
count was 185 G/L (p25: 145 G/L - p75 238 G/L). During routine follow-up, 28 patients had low blood cell 
count values with 19 patients with median ANC below 0.5 G/L, 11 with a platelet count below 100 G/L and 
7 with chronic anemia (hemoglobin below 9 g/dL). Bone marrow smears were available at baseline for 81 
patients and granulopoietic blockage was observed in 20 patients (24.7%) while the others had differential 
counts within the normal range. Of note, routine bone marrow smears commonly presented granulopoietic 
abnormalities, with condensed chromatin and nuclear hyposegmentation (online supplementary figure 2).  
Among the 81 patients with assessable immunoglobulin levels, one patient had low values (between -2SD 
and -3SD for age), but did not require immunoglobulin infusions. In contrast, polyclonal 
hypergammaglobulinemia was found in 52 patients (65%). The median lymphocyte count was 3.3 G/L 
(p25: 2.5 G/L - p75: 4.5 G/L). 
Forty-three patients presented at least one episode of severe infection (42%). Median age at the first 
infection was 9.6 years (p25:2.4 years - p75: 16.9 years). The Kaplan-Meier plot (data not shown) showed 
that first severe infections were most frequent in childhood but continued to appear until the fourth decade. 
A total of 72 severe infections were recorded and consisted of pneumonia in 30 cases, cellulitis in 26 
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cases, sepsis with bacteremia in 19 cases (associated with other infections in 8 cases), osteoarthritis in 3 
cases, meningitis in 1 case, and colitis in 1 case. Acute stomatitis occurred in 13 patients. No chronic 
periodontal disease was reported. Three cases of severe viral infections were reported: one of malignant 
varicellae, one lethal case of measles, and one case of influenza with cardiomyopathy.  
 
Hematological complications 
A total of 41 patients presented a hematological complication, listed in detail in table 1. In 21 cases, 
definitive SC occurred and was classified as malignant cytopenia in nine cases, non-malignant in nine, 
while three cases presented first a non-malignant SC and subsequently a malignant SC, resulting in a 
total of 12 cases of malignant SC and 12 cases of non-malignant SC. 
In the 12 patients with malignant SC according to the WHO 2008 classification, the cytologic bone marrow 
features were acute myeloid leukemia (AML) with MDS-related changes in eight cases (FAB M2 in 2; FAB 
M4 in 2, FAB M6 in 3 and FAB M0 in one); refractory cytopenia with multilineage dysplasia in three cases, 
MDS with refractory anemia with excess blasts (RAEB 1) in one case. The most frequent cytogenetic 
feature of patients with leukemia and MDS was the monosomy 7, found in six of the twelve cases. Notably, 
the cytogenetic abnormality consisted of an isolated i(7)(q10) in two patients. In the 12 cases of non-
malignant SC, two had presented with almost complete bone marrow aplasia, five with bone marrow 
hypoplasia involving all hematological lineages, three with bone marrow hypoplasia and arrest of 
granulopoiesis, one with isolated maturation arrest and one with hypoplasia and mild dyserythropoiesis.  
In three cases, non-malignant SC, managed by repeat transfusions and G-CSF, was subsequently 
complicated by MDS. The three patients, who had sequentially presented with non-malignant then 
malignant SC, were newborns at diagnosis; the bone marrow aspect exhibited dramatic changes, 
concomitant with the onset of a bone marrow cytogenetic clone.  
Malignant and non-malignant SC had a different demographic pattern as malignant complications 
occurred at a median age of 11.1 years (p25: 4.1 years - p75: 24.6 years) while the non-malignant SC 
occurred at median ages of 0.13 years (p25: 0.01 year - p 75: 3.3 years). Figure 1a depicts the 
occurrence of the risk of SC and shows that the risk is not constant throughout life; there is a high 
incidence below 1 year of age and then the risk decreases with age until 15 years. It appears to be more 
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constant below 15 years, but never achieves a plateau. Twenty-year cumulative risk of SC was 24.3% 
(95% CI 15.3%-38.5%). The Kaplan-Meier plot of these two complications included in figures 1b and 1c 
accentuates the different timing of onset: non-malignant SC occurred early in life and never after 15 years 
of age (figure 1b), while malignant SC appeared throughout life, even after the age of 30 (figure 1c). 
Overall, definitive SC was responsible for 15 of the 17 deaths observed in the cohort and the 6 survivors 
of SC all underwent hematopoietic stem cell transplantation (HSCT).  
In contrast, the 21 patients who had transient SC or clonal bone marrow findings without SC had a good 
outcome. In 12 cases, the SC was transient, recovering in less than three months. Bone marrow smears 
and cytogenetic analyses were performed in six such cases. In one case, morphological myelodysplasia 
was observed but without clonality, and the patient shortly recovered normal hemoglobin and platelet 
counts However, once hematological recovery was achieved, the hematological situation was stable, 
except in one patient who presented with another new episode of definitive non-malignant SC eight years 
later. Transient SC was suggestive of viral infection, but in all cases, common viral infections such as 
parvovirus, Epstein–Barr virus (EBV), and cytomegalovirus (CMV) were excluded. Such transient severe 
complications occurred at the median ages of 0.83 years (p25: 0.28 years - p75: 3.4 years). 
In nine patients without SC, the hematological complications consisted of the presence of cytogenetic 
clones on routine bone marrow surveillance. Although bone marrow smears showed mild 
dysgranulopoietic features, they did not exhibit MDS/acute leukemia criteria. The cytogenetic clone 
consisted of i(7)(q10) in 3 patients and del(20 q) in 5 patients. In two patients a more complex cytogenetic 
anomaly was observed with an indolent outcome. The cytological features observed in such cases were 
not different to those observed on routine bone marrow smears, involving condensed chromatin and 
nuclear hyposegmentation (supplementary figure 2), occasionally hypoplastic. 
G-CSF was used to prevent infections in 17 patients (in addition to its use for SC or in a post-transplant 
period), at a mean dose of 4.8 µg/kg (0.5–10 µg/kg). In most cases, G-CSF was used “on demand”, i.e. 
when an infection occurred. Only seven patients received long-term G-CSF therapy. HSCT was 
performed in 12 patients, for malignant (n=6) or non-malignant (n=6) SC as reported previously.5 
Seventeen deaths were recorded (15%), at a median age of 6.5 years (min-max: 0.2 - 33.7 years). The 
survival plot showed higher mortality rates before five years of age and also in the third decade and the 
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20-years survival rate observed was 85% (95% CI: 76%- 92%) (Supplementary figure 3). The two deaths, 
not related to a SC, were the consequence a measles infection with a myocardiopathy, and a traffic injury, 
potentially provoked by orthopedic difficulty at age of thirteen. 
 
SBDS mutations and genotype-phenotype relationships 
The mutational spectrum in the 93 probands is reported in tables 2A and 2B. The p.Lys62X and p.Cys84fs 
mutations, resulting from conversion events between the SBDS gene and its highly homologous 
pseudogene, represented 86% (157/186 alleles) of the causal mutations. The genotypes 
p.[Lys62X]+[Cys84fs] and p.[Lys62X;Cys84fs]+[Cys84fs] were present in 61% and 6% of the patients, 
respectively.  
The other molecular events were point mutations, consisting mainly of missense mutations (17/29), 
nonsense mutations (2/29), frameshift mutations (4/29), in-frame deletions (1/29) and splice defects (5/29). 
Two-thirds of rare events were novel and affected highly conserved residues (table 2A). The p.Cys84fs 
mutation was significantly more frequent than the p.Lys62X mutation in compound heterozygotes, 27% 
and 5% respectively. We compared the 67% of patients who had the two recurrent genotypes with 
patients who had other genotypes (33%). No significant difference was observed in the distribution of 
hematological parameters, infectious events, death and non-hematological features (data not shown). The 
rate of SC was not statistically different among patients with the frequent genotype p.[Lys62X]+[Cys84fs] 
than in patients with the other compound heterozygous genotypes (P=0.41). One important finding 
arguing against a close phenotype-genotype relationship in SDS is the lack of clinical concordance in the 
eight multiplex families (Online Supplementary Table 1), as five sib pairs were concordant for severe 
cytopenia, while three were discordant.  
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Risk factors for leukemia and bone marrow failure 
The following parameters were studied: gender, age at diagnosis, intrauterine growth retardation (≤3DS), 
severe gastrointestinal complications, severe developmental retardation, initial and baseline blood 
parameters categorized as severe neutropenia (if absolute neutrophil count < 0.5 G/L), mild 
thrombocytopenia (if platelet count < 100 G/L), and mild anemia (if Hb < 9 g/dL), transient SC, cytogenetic 
clone, orthopedic complication, prophylactic G-CSF use. Univariate analysis is summarized in table 3.  
Among 12 variables studied (table 3), the analysis showed that three of them had deleterious prognostic 
value with a P value ≤0.001, namely the age at diagnosis and the hematological parameters both at 
diagnosis and during routine follow-up. Severe gastrointestinal complications are associated with a high 
risk of SC but the P value is higher than for other significative factors (P=0.016). Gender, intrauterine 
growth retardation, severe neurological development delay, transient SC, cytogenetic clone without SC, 
orthopedic complications, G-CSF prophylactic use and genotype did not have significative impact. 
Finally, taking into consideration both the age and complete blood count at diagnosis, it was possible to 
distinguish three subgroups according to the risk of hematological complications. The three groups are the 
(i) the low-risk group: patients with age of diagnosis ≥ 3 months and no low value on the three parameters 
(ANC ≥ 0.5 G/L and/or Hb ≥9 g/dL and/or platelets ≥100 G/L); (ii) the intermediate-risk group: patients with 
age of diagnosis <3 months or at least one low value on the initial CBC (ANC <0.5 G/L and/or Hb <9 g/dL 
and/or platelets <100 G/L) and (iii) the high-risk group (patients with age of diagnosis < 3 months and at 
least one low value on the initial CBC (ANC < 0.5 G/L and/or Hb <9 g/dL and/or platelets <100 G/L). The 
10-year and 20-year risks of SC were 0%, 12.6 %, 58.6 % and 6.2%, 34.4% and 58.6%, respectively, in 
the three groups (P<0.0001, figure 2). Lastly, the three groups also had a different dynamic of severe 
hematological complications as the high-risk group was exposed in the first decade, the intermediate-risk 
group later, with SC presenting during the second decade, while the low-risk group presented SC in their 
third decade. 
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Discussion 
We studied a large cohort of 102 patients with SDS through our national registry. The long-term follow-up 
period allowed us to observe the hematological complications and to identify risk factors for SC.  
To describe and to classify the hematological complications, we reviewed for all patients all the 
hematological parameters obtained longitudinally, the complete blood counts, the bone marrow smears 
classified, after a central review, according to the more recent revision of the WHO classification of 
myelodysplasia13;14 and the cytogenetic bone marrow findings. Our findings show that the major 
hematological complications in SDS are a definitive dysfunction of hematopoiesis, either malignant or non-
malignant, which is lethal in the absence of HSCT. Conversely, mild abnormalities, not lethal, are 
observed by the incidental detection of cytogenetic clone on bone marrow and by a transient dysfunction 
of hematopoiesis. In our study, among the 21 patients who experienced a definitive SC, only six patients 
survived, after receiving a HSCT. In contrast, among the 21 patients who presented a mild hematological 
complication, all survived, and only in one case, the patient had presented later with a severe 
hematological complication (a non malignant SC – which was cured by a HSCT). Our observations are 
concordant with case reports reviewed by Dror1 and classified into 4 distinct groups: cytopenia, 
myelodysplasia, leukemia and cytogenetic abnormalities. The situation described as cytopenia was also 
named by several authors as ‘aplastic anemia’,17-23 despite many cases not fulfilling the classical criteria of 
severe aplastic anemia.24 In SDS, an additional complexity is related to cytogenetic abnormalities 
observed incidentally during routine bone marrow surveillance. Two recurrent cytogenetic anomalies are 
observed, i(7)(q10) and del(20q), which can be indolent and eventually transient.25-33 But the same 
abnormalities can also announce or be associated with a frank malignant outcome,34-36 as we observed in 
two cases in this survey. In addition to i(7)(q10) and del(20q), we observed a same indolent profile in two 
patients, one with t(16;20) in addition to i(7)(q10) and one with a complex abnormality of the chromosome 
9 (table 1).  
With regards to the difficulties in classifying the hematological complications undoubtedly related to the 
underlying disease, our work shows that the WHO classification of myelodysplasia can be applied to 
define the malignant complications of SDS13-15 but needs to be completed by a category which can be 
simply defined as non-malignant SC, a category frequently named ‘aplastic anemia’.17-23 The terminology 
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non-malignant SC was preferred to aplastic anemia, because routine bone marrow of SDS patients 
exhibited dysgranulopoeitic features or abnormalities of granulopoeitic maturation. As in Fanconi anemia, 
the dyserythropiesis hyposegmentation or condensed chromatine have not be considered as a sign of 
myelodysplasia,37 except if it was observed in more than 50% of the neutrophils. 
Indeed, the hematological complications need to encompass mild abnormalities constituted by the 
incidental detection of cytogenetic clone on bone marrow and by a transient dysfunction of hematopoiesis. 
In such a case, spontaneous recovery is a key feature and needs to be observed by month three.  
We then analysed the risk factors that may influence the occurrence of severe hematological 
complications, as they constitute so far the major causes of early death in patients with SDS. First, we 
analysed the relationships between the genotype and the occurrence of hematological complications. Until 
now, only four studies38-41 had both reported information about SBDS genotypes and a survey of patients 
including cases with SC. These four studies represent a total of 47 patients, among whom nine cases of 
malignant SC and two cases of non-malignant SC were observed, showing no particular association 
between genotype and SC. In this large cohort of 102 genotyped patients, we excluded a correlation 
between the genotype and the development of SC. This is not surprising since the two recurrent 
genotypes are observed in two-third of patients. 
Secondly, we analysed hematological and clinical parameters. Our analysis showed that the prognostic 
factors of SC are significantly associated with the age at first symptoms and with hematological 
parameters, but did not correlate with gender or with other associated features characterizing the disease.  
This led us to propose a classification of the severity of SDS based on the first blood counts (taking into 
account the first 3 CBC in order to exclude outlier values) and on the age of diagnosis (< or ≥ 3 months). 
Patients diagnosed as SDS before the age of three months and with low hematological parameters at 
diagnosis have a higher risk of major hematological complications than patients diagnosed after three 
months and without low values of CBC, or with only one of these features. Consequently, the occurrence 
of SC was respectively in the two groups 13% and 0% after 10 years and 59% and 33% after 20 years of 
evolution.These results need to be validated by other studies on different cohorts of patients but it offers a 
simple way to identify patients at high-risk of severe hematological complications, at the time of their 
diagnosis.  
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Early identification of patients at risk for hematologic complications may be useful if any consider the 
possibility offered by the hematopoietic stem cell transplantation (HSCT). To date HSCT  is proposed only 
in case of severe cytopenia42. But the results of transplants appear highly contrasted, according to the 
indication of the graft. Despite the small number, a significant difference in survival between patients 
receiving HSCT for non malignant SC and those undergoing the procedure for leukemic transformation. 
Taking into account 33 published original cases5;18;22;23;25;43-55 of HSCT for SDS for which this information 
is mentioned, the survival after HSCT is significatively (p<0.001) different among the 22 patients with MDS 
/ acute leukemia (17 deaths) vs. the 11 patients with non malignant severe cytopenia (1 death). Several 
factors may explain the poor results of HSCT for myelodysplasia/acute leukemia in SDS and age 
appeared to be an important factor, as malignant SC occurred in older patients, while several associated 
morbidities progress with age in this setting, including the nutritional consequences of exocrine pancreatic 
insufficiency.  In order to improve the results of the HSCT, pre emptive transplantation has been proposed 
early in life 56 in order to prevent hematological complications, with a limited toxicity. Our study is the first 
to identify prognostic factors of severe hematological complications in SDS. If these results are confirmed,  
it would be possible then to consider a program of pre emptive HSCT for SDS patients at high-risk of 
severe cytopenia, early in life. 
In conclusion, our study defines in a population-based survey, the hematological complications observed 
in SDS, based on the central review of all available materials which can be collected in SDS patients. This 
study showed that the risk of severe and potential lethal complications in SDS is extremely high, up to 
25% by age of 20 years, while no other malignancy is observed, in contrast to Fanconi anemia. The 
hematological complications were correlated with the hematological blood counts collected at diagnosis 
and with the age of first symptoms, offering a simple tool to classify patients with SDS with regards to the 
risk of hematological complications. A potential use could be a pre emptive hematopoietic stem cell 
transplantation program for the patients at high risk of hematological complications. 
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18 CH Saintes, Service de Pédiatrie, Saintes, France 
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27 CHU Nice, Département de Pédiatrie, Nice, France 
28 CHU Nantes, Hématologie, Nantes, France 
29 Cabinet de Pédiatrie, Pessac, France 
30 CH Hyeres, Service de Pédiatrie, France 
31 APHP, Hôpital Saint Louis, Département d’Immuno-Hematologie, Paris, France 
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 Legends 
Table 1.  Detailed description of the patients with hematological complications, sorted by type of 
complications: Severe cytopenia malignant, Severe cytopenia non malignant, Cytogenetic clone without 
severe cytopenia, transient severe cytopenia. 
 
Table 2.  A: Details of allelic changes, including the nucleotide sequence changes and deduced 
consequences at the protein level. The results are given for the 102 patients belonging to 93 families. 
Each allele was counted only once per multiplex family.  
B: Distribution of the genotypes among the 93 affected families, classified by the consequences of allelic 
changes. 
 
Table 3.  Univariate prognosis analysis. The end point was severe cytopenia (malignant and non-
malignant together) and the p value is the p value of the log rank test. 
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Table 1.  
 
 UPN SBDS Genotype Age* Bone marrow cytology Review Bone marrow Karyotype  
Follow-up after 
the event (y) 
Outcome 
(alive/HSCT/ cause of death) 
Malignant SC 
5617 p.[Lys62X]+[Cys84fs] 2.5 AML with MDS related changes FAB type AML2 Monosomy 7 0.3 
Death / no HSCT 
5057 p.[Lys62X]+[Cys84fs] 26.3 AML with MDS related changes FAB type AML2 
43,XY,-5,-7,-13,-16,-18,-20,+3mar[5] /51,XY,+1,-5,-
7,+10,+10+21,+3mar[2] / 46,XY,del(20)(q11q13)[2] 0.5 
Death / AML / no HSCT 
5081 p.[Lys62X]+[Cys84fs] 27.2 AML with MDS related changes FAB type AML4 45, XX,add(1)(p11),-7,add(14)(q32),add(21)(q22)[20] 0.58 
Death / HSCT / viral infection after 
HSCT 
5073 p.[Lys62X]+[Cys84fs] 32.4 AML with MDS related changes FAB type AML6 
41-46,XY,-5,-7,-15,-16,-
19,+der(3)(?),+der(6)(?),del(13)(q13q33),der(20)(?),+r(?),+mar1
,+mar2 [cp31] 
1.29 Death / AML/ no HSCT 
5253 p.[Cys84fs]+c.[290-1G>A] 7.3 AML with MDS related changes FAB type AML6 45,XY,del(5)(q ?q?),add(9)(q ?),+11,add(17)(p ?),-20,+22 0.42 
Death / HSCT / viral infections after 
HSCT 
5038 p.[Lys62X]+[?] 19.1 AML with MDS related changes FAB type AML6 
46,XY[1]/45,XY,del(5)(q15q33),-
7,+?mar[1]/44,XY,der(3)t(3;6)(?;?),del(5)(q?q?),-6,-7[19] 1.9 
Death/ HSCT / Death related to MDS 
relapse 
5023 p.[Lys62X]+[Cys84fs] 22.9 AML with MDS related changes FAB type AML0 46,XY,add(15)(p?)/44,idem,-20,-21,-22,+mar[20]/46,XY[3] 1.41 Death / no HSCT 
5117 p.[Lys62X]+[Cys84fs]  7.6 Refractory cytopenia with multilineage dysplasia 
46,XY,del(1)(p36),t(3;21)(q26;q11),del(5)(q21q24),del(7)(q21q
35),+del(8)(p21),-18[15]/46,XY[10] 1.36 
Death / HSCT / Death related to MDS 
relapse 
5082 p.[Cys84fs]+[Gln94_Val95del] 15.9 Refractory cytopenia with multilineage dysplasia isochromosome 7q 12.8 Alive / HSCT  
Non-
malignant 
followed by 
malignant SC 
5737 p.[Cys84fs]+c.[129-71_140del83] 
0.1 Hypoplastic no abnormality 1.5 Death / / no HSCT – supportive care 
1.1 MDS (AREB 1) Monosomy 7 0.43 Death after HSCT / toxicities of HSCT Cond. regimen 
5208 p.[Lys62X]+[Cys84fs] 
0.1 Hypoplastic granulopoeitc maturation arrest  no abnormality 1.01 Death / secondary MDS 0.5 year after initial event 
0.4 Refractory cytopenia with multilineage dysplasia 46,XY,i(7)(q10)[10]/46,XY[10]   0.57 Death from MDS / no HSCT 
5437  p.[Cys84fs]+[Arg169Leu] 
0.2 Hypoplastic granulopoeitc maturation arrest no abnormality 6.30 Death / no HSCT / secondary AML 6 y after initial event 
6 AML with MDS related changes FAB type AML4 
46,XY,add(7)(q31)[15]/46,XY[1].ish 
der(7)t(1;7)(q32;q31)(WCP7+,WCP1+) 0.5 Death from AML /no HSCT 
Non-
malignant 
definitive SC 
5263 p.[Lys62X]+[Cys84fs] 0.05 Aplastic no abnormality 10.4 Alive after HSCT 
5855 p.[Lys62X]+[Cys84fs] 0.1 Aplastic no abnormality 0.21 Death / supportive care respiratory distress 
5170 p.[Lys62X]+[Cys84fs] 0.4 Hypoplastic no abnormality 10.3 Alive after HSCT 
5512 p.[Lys62X]+[Cys84fs] 0.2 Hypoplastic no abnormality 8.3 Alive after HSCT 
5128 p.[Cys84fs]+[Cys119Arg]  12.2 Hypoplastic  no abnormality 22.1 Alive after HSCT 
5184 p.[Lys62X]+[?] 5.9 Hypoplastic with mild dyserythropeisis features no abnormality 17.1 Alive after HSCT 
5589 p.[Cys84fs]+[Glu99fs]  0.1 Hypoplastic with dysgranulopoeitic features no abnormality 1.9 Death / no HSCT 
5770 p.[Cys84fs]+[exon 2 deletion] 0.73 Normally rich bone marrow no blast Granulopoeitc Maturation arrest  no abnormality 0.37 Death / no HSCT 
Transient then 
definitive SC 5098 p.[Cys84fs]+c.[624+1G>C] 
8 No BM smear Not done 17.2 Definitive not clonal SC 7/9 years after 
15.6 Hypoplastic no abnormality 9.67 Alive after HSCT 
Transient SC 
5154 p.[Lys62X]+[Cys84fs] 1.6 No BM smear Not done 13.8 Stable situation 
5139 p.[Lys62X]+[Cys84fs] 0.4 Hypoplastic  no abnormality 16.4 Stable situation 
5171 p.[Lys62X]+[Cys84fs] 6.5 No BM smear Not done 8.3 Stable situation 
5207 p.[Lys62X]+[Cys84fs] 0.28 Hypoplastic  no abnormality 19.3 Stable situation 
5504 p.[Lys62X]+[Lys148Thr]  0.9 Dysmyelopoietic features hemophagocytosis  no abnormality 8.4 Stable situation  
5777 p.[Cys84fs]+[Pro6Leu]  3.4 
No BM smear after CBC normalisation 
hypoplastic with dysgranulopoietic features + 
neutrophil phagocytosis 
Not done 4.3 Stable situation 
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5180 p.[Lys62X]+[Cys84fs] 0.2 Erythroblastopenia No abnormally 20 Stable situation 
5254 p.[Cys84fs]+[Cys119Tyr] 0.4 No BM smear Not done 49 Stable situation 
5620 p.[Lys62X]+[Cys84fs] 0.13 No BM smear Not done 6.31 Stable situation 
7011 p.[Lys62X]+[Cys84fs] 0.1 Maturation arrest No abnormally 0.3 Stable situation 
5764 p.[Lys62X]+[Cys84fs] 0.75 Maturation arrest no abnormality 3.25 Stable situation 
Bone marrow 
cytogenetic 
clone without 
SC 
5074            p.[Lys62X]+[Cys84fs] 26.5 Rich mild dysgranulopoiesis and dysmegacaryopeitic  46,XX,del(20)(q11q13)[10]/46,XX[20] 10.7 Stable situation 
5321 p.[Lys62X]+[Cys84fs] 5.6 Rich mild dysgranulopoiesis with bilobated nuclei / segmentation defect  46,XY,del(20)(q1?1)[6]/46,XY[28] 3.7 Stable situation 
5519          p.[C84fs]+[Arg218Gln]  6.5  Poor Mild dysgranulopoiesis with bilobated nuclei / segmentation defect 46,XY,t(16;20)(q24;q11.2)[2]/46,XY,i(7q) [1]/46,XY[17] 7.4 Stable situation 
5571 p.[C84fs]+[Arg218X]  13.6 Poor Mild dysgranulopoiesis with bilobated nuclei / segmentation defect 46,XY,del(20)(q?)[7]/46,XY[23] 5.3 Stable situation 
5670 p.[C84fs]+[Phe57Leu]  3.7 Rich Mild dysgranulopoiesis with bilobated nuclei / segmentation defect isochromosome 7q 1.1 Stable situation 
5715         p.[C84fs]+[Gln103fs]  2.8 Rich Mild dysgranulopoiesis with bilobated nuclei / segmentation defect 46,XY,del(20)(q1?2)[16]/46,XY[4] 2.14 Stable situation 
5579 p.[C84fs]+[exon 2 deletion]  7.56 Rich Mild dysgranulopoiesis with bilobated nuclei / segmentation defect 
46,XX,?dup(9)(p13)[?6]/46,XX[24] 
44,X,-X,add(9)(p22),-13,-14,-14,+2mar[2]/46,XX[18] 4.8 Stable situation 
6251 p.[Cys84fs]+[Cys19Thr] 22.5 Rich Mild dysgranulopoiesis with bilobated nuclei / segmentation defect 46,XX,i(7)(q10)[12]/46,XX[8] 0.5 Stable situation 
5451 p.[Lys62X]+[Cys84fs] 5.5 Poor Mild dysgranulopoiesis with bilobated nuclei/ segmentation defect 46,XX,del(20)(q12)[4]/46,XX[29] 6 Stable situation 
Abbreviation: HSCT: Hematopoietic Stem Cell transplantation; AML: Acute Myeloid Leukemia; MDS: Myelodysplasia; FAB: French American British classification of leukaemia; RAEB: 
Refractory anemia with excess blasts; BM, bone marrow; * age at eve
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Table 2A.  
Location Nucleotide sequence change Protein effect Type of mutation 
Number of 
alleles Percentage References 
Exon 1 c.13delA p.Thr5fs Frameshift mutation 1 < 0.01 This report 
Exon 1 c.17C>T p.Pro6Leu Missense mutation 1 < 0.01 This report 
Exon 1 c.56G>A p.Arg19Gln Missense mutation 1 < 0.01 48 
Exon 1 c.95 A>G p.Tyr32Cys Missense mutation 1 < 0.01 49 
Intron 1 c.129-2A>G p.? Splice defect 1 < 0.01 This report 
Intron 1 c.129-1G>A p.? Splice defect 1 < 0.01 This report 
Exon 2 c.129-71_140del83 p.? Splice defect 1 < 0.01 This report 
Exon 2 c.164C>A p.Ser55X Nonsense mutation 1 < 0.01 This report 
Exon 2 c.171T>A p.Phe57Leu Missense mutation 1 < 0.01 This report 
Exon 2 c.183_184delinsCT p.Lys62X Nonsense mutation 58 0.31 2 
Exon 2 c.[183_184delinsCT; 258+2T>C] p.[Lys62X;Cys84fs] Nonsense mutation 6 0.03 
2 
Exon 2 c.129-?_258+? p.? Exon 2 deletion 1 < 0.01 This report 
Intron 2 c.258+1G>A p.Cys84fs Splice defect 1 < 0.01 2 
Intron 2 c.258+2T>C p.Cys84fs Splice defect 90 0.49 2 
Exon 3 c.279_284del p.Gln94_Val95del In-frame deletion  1 < 0.01 48 
Exon 3 c.297_300delAAGA p.Glu99fs Frameshift mutation 2 0.01 50 
Exon 3 c.307_308delCA p.Gln103fs Missense mutation 1 < 0.01 49 
Exon 3 c.355T>C p.Cys119Arg Missense mutation 1 < 0.01 This report 
Exon 3 c.356G>A p.Cys119Tyr Missense mutation 3 0.02 This report 
Exon 3 c.385A>G p.Thr129Ala Missense mutation 1 < 0.01 This report 
Exon 3 c.443A>C p.Lys148Thr Missense mutation 1 < 0.01 48 
Exon 3 c.453A>C p.Lys151Asn Missense mutation 1 < 0.01 This report 
Exon 3 c.461C>T p.Ala154Val Missense mutation 2 0.01 This report 
Intron 3 c.460-1G>A p.? Splice defect 1 < 0.01 48 
Exon 4 c.506G>T p.Arg169Leu Missense mutation 2 0.01 This report 
Intron 4 c.624+1G>C p.? Splice defect 1 < 0.01 48 
Exon 5 c.652C>T p.Arg218X Nonsense mutation 1 < 0.01 51 
Exon 5 c.653G>A p.Arg218Gln Missense mutation 1 < 0.01 This report 
   Undetermined mutation* 2 0.01  
        186    
*In two patients with a documented SBDS phenotype, only one heterozygous SBDS mutation was found.   
 
Table 2B.  
    
Genotype Occurrence Percentage 
p.[Cys84fs]+[Lys62X] 56 62 
p.[Cys84fs]+[Lys62X;Cys84fs] 6 6.5 
p.[Cys84fs]+[Cys84fs] 1 1 
p.[Cys84fs]+[nonsense, frameshift mutation] 8 9 
p.[Cys84fs]+[splice defect] 5 5 
p.[Cys84fs]+[missense mutation] 12 13 
p.[Cys84fs]+[in-frame deletion] 1 1 
p.[Lys62X]+[missense mutation] 1 1 
p.[Lys62X]+[undetermined mutation] 2 1 
p.[Ala154Val]+[Ala154Val] 1 1 
    93   
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Table 3 . 
Variables Modality No. at risk 
Observed/ 
Expected 
Hazard  
ratio p value 
Gender Male Female 
57 
45 
13/10.6 
8/10.4 1.6 0.3 
Age at diagnostic 
< 3 months 
3 months – 3 years 
3 years 
35 
49 
18 
12/4.3 
6/11.5 
3/5.2 
7.3  
.99 
1 
0.0001 
Genotype [Cys84fs]+[Lys62X]  Others 
62 
38 
13/14.4 
8/6.5 0.75 0.41 
CBC at diagnosis: ANC < 0.5 G/L  Yes No 
23 
79 
8/4 
13/19 2.54 0.02 
CBC at diagnosis: Platelets < 100 G/L Yes No 
11 
91 
7/1.9 
13/18 5.9 <0.0001 
CBC at diagnosis: Hemoglobin < 9/g/dL  Yes No 
13 
89 
4/2.1 
17/19 2.2 0.15 
CBC at diagnosis – at least one low value Yes No 
38 
64 
14/6.6 
7/14.3 4.4 0.0005 
Routine CBC: ANC < 0.5 G/L  Yes No 
19 
83 
9/2.6 
12/18.4 5.5 <0.0001 
Routine CBC Platelets < 100 G/L Yes No 
11 
88 
9/.2 
11/17.9 7.3 <0.0001 
Routine CBC Hemoglobin <9 g/dLl Yes No 
3 
90 
2/0.16 
143/14.73 17 <0.0001 
Routine CBC – at least one low chronic value Yes  No 
25 
77 
14/3.65 
7/17.35 10.2 <0.0001 
Transient Severe Cytopenia Yes No 
12 
90 
1/2.5 
20/18.4 0.35 0.29 
Cytogenetic clone without Severe cytopenia  Yes No 
9 
93 
0/2 
21/19 * 0.19 
G-CSF3 – prophylactic – at baseline No Yes 
85 
17 
2/3.51 
19/17.5 0.52 0.37 
Gastrostomy or parenteral nutrition Yes No 
19 
83 
6/2.5 
15/18.5 3.25 0.013 
Severity Score:  
 
Low risk 
Intermediate risk 
High risk 
44 
43 
15 
3/11.3 
10/7.8 
8/1.65 
1 
5.9 
27.5 
< 0.0001 
 CBC: Complete blood count; ANC: Absolute neutrophil count; G-CSF: Granulocyte-Colony stimulating Factor; Severity score: High 
risk if age at diagnosis < 0.25 years and if at diagnosis CBC with a low value /Intermediate if diagnostic age < 0.25 years and if at 
diagnosis CBC with a low value / Low risk if diagnostic age >= 0.25 years and if no low value at diagnosis CBC 
* Intrauterine growth retardation (≤3 SD), severe developmental retardation, orthopedic complications have been assessed and did 
not provide any prognostic information. 
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Figure 1. Kaplan-Meier plot showing the risk of severe cytopenia. The events in figure 1a are any severe cytopenia, in figure 1b the non-malignant 
severe cytopenia and in figure 1c the malignant severe cytopenia (MDS/ leukemia). The time is expressed in years since birth. 
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Online Supplementary Table 1. Main clinical features of the 10 pairs of siblings. All the patients carried the p.[Lys62X]+[Cys84fs] genotype, 
except for two families, one* with the p.[C84fs]+[Pro6Leu] genotype and one** with p.[Cys84fs]+[large deletion]. The concordance among siblings 
is shown in the right-hand column in terms of major hematological events and also morphologic and developmental features. 
 
UPN 
 
Sex Age at 
diagnosis  
(y) 
Age at last follow 
up / vital status + 
cause of death 
Severe cytopenia 
(age) 
Major Gastro 
intestinal 
complications 
Major 
developmental 
impairment 
Bone 
complications 
Heart abnormalities Baseline 
ANC median G/l 
Baseline 
platelets 
median G/l 
Concordance 
for SC 
5073 M 0.29 33.7 D (AML) Yes clonal (MDS) No No No Yes (aortic coarctation) 0.510 
152 
No 
5074 F 23 39 L – mother of 3 children 
No (but isolated 
transient del 20q) No No No No 0.768 
180 
5616 F 0.73 1.3 D (sepsis during measles)  No Yes No No No 0.215 
54 Yes 
both with severe 
expression but 
AML in only one 
5617 
 F 0.02 2,3 D (AML) Yes AML like (2.1) No No No No 1.040 
_ 
5438* M* 0.9 2.5 L No No No No No 0.595 275 
Yes 5439* 
 M* 0.9 2.3 L No No No No No 0.660 
258 
5171 M 2.2 11.9 L No No No No No 0.574 261 
No 5170 
 M 0.3 9.7 L Yes SC not clonal Yes Yes No No 0.392 
125 
5062 F 0.4 30L No No No No No 0.886 166 
Yes 5063 
 F 1.05 
38 L – mother of two 
children No No No No No 0.566 
154 
5029  M 0.13 17 L No No Yes Yes No 0.864 341 Yes 
 5030  M 0.54 12 L No No No No No 0.784 
191 
5769 F 0.22 0.7 D sepsis No No No No No 0.694 401 
No 
(severe 
expression in 2/3) 
5570 F 0.06 1.1 D sepsis  Yes  No Yes severe seizure No Cardiomyopathy 0.825 
459 
5579 
 F 0.15 8.4 L  No No No No No 0.595 
275 
5777 M 7.6 8.6 L No No No No No 0.885 186 
Yes 5778 
 M 4.5 5.6 L No No No No No 1.577 
244 
UPN: unique patient number; M: Male; F: Female; L: Living; D: Dead, ANC: Absolute Neutrophil Count; AML: Acute myeloid leukemia; SC: Severe cytopenia 
*monozygotic twins 
 
DOI: 10.3324/haematol.2011.057489
Online supplementary figure 1. Long term outcome of routine absolute neutrophils count in two unrelated patients bearing the same mutation 
p.Lys62X p.Cys84fs.  
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 Online supplementary figure 2. a: Marrow smear in a patient with Shwachman-Diamond syndrome complicated by bone marrow aplasia: poor 
cellularity, fat cells and mast cells. b: Marrow smear in a patient with Shwachman-Diamond syndrome complicated by acute erythroid leukemia 
(FAB AML 6). c:Transient not clonal SC with granulopoiesis maturation arrest. d: Marrow smear in a patient with Shwachman-Diamond syndrome 
complicated by cytopenia and monosomy 7 (RAEB-1). Top panel: Dyserythropoiesis: karyorrhexis, multinuclearity, internuclear bridging, 
megaloblastoid changes. Lower panel: Dysgranulopoiesis: nuclear hypolobulation, cytoplasmic hypogranularity, dual nuclear and blast 
e:Marrow smear in a patient with Shwachman-Diamond syndrome transient severe cytopenia with transient dysmyelopoietic features Up: dual 
nuclear Low: micromegakaryocytes with non-lobated nuclei. f: Neutrophils on marrows smears in 3 patients with Shwachman-Diamond syndrome 
and one control showing condensed chromatin and nuclear hyposegmentation and in one control. For each bone marrow, the proportion of 
neutrophils with condensed chromatin and nuclear hyposegmentation was counted . Top left: example in a patient with SC but non malignant 
(mean: 34%) 
Top right: example in a patient without SC with cytogenetic abnormality (mean: 26%). Below and left: example in SDS without SC and without 
cytogenetic (mean: 20%). Below and right: without SDS (mean: 4%). 
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Online supplementary figure 3. Kaplan-Meier plot showing the overall survival of the cohort of 102 patients. The time is expressed in year  
since birth. 
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